Background. This phase 4, randomized, placebo-controlled, double-blind, study evaluated immune responses after coadministration of 13-valent pneumococcal conjugate vaccine (PCV13) and a quadrivalent inactivated influenza vaccine (QIV) in adults aged ≥50 years previously immunized with 23-valent pneumococcal polysaccharide (PPSV23).
Background. This phase 4, randomized, placebo-controlled, double-blind, study evaluated immune responses after coadministration of 13-valent pneumococcal conjugate vaccine (PCV13) and a quadrivalent inactivated influenza vaccine (QIV) in adults aged ≥50 years previously immunized with 23-valent pneumococcal polysaccharide (PPSV23).
Methods. Subjects received PCV13 + QIV then placebo 1 month later (group 1) or placebo + QIV then PCV13 1 month later (group 2). Opsonophagocytic activity (OPA) geometric mean titers (GMTs) and hemagglunation inhibition assay (HAI) GMTs for 13 pneumococcal serotypes and 4 influenza strains, respectively, were assessed before and 1 month after vaccination. The prespecified noninferiority criterion was 2-fold (0.5 lower limit of 95% CI for GMT ratios). Adverse events (AEs) and serious AEs (SAEs) were assessed.
Results. The evaluable immunogenicity population in groups 1 and 2 comprised 421 and 425 subjects, respectively (mean age, years [±SD] , 67.0 [±9.08] and 66.4 [±8.84]); >93% of subjects had received ≥1 PPSV23 dose. The noninferiority criterion was met for OPA GMTs for all 13 pneumococcal serotypes (table 1) . In most cases, GMT point estimates were lower when PCV13 was coadministered, with significantly lower GMTs (upper limit of the 95% CI <1 on the GMT ratio) for serotypes 3, 4, 6A, and 14. Baseline HAI GMTs were similar between groups and rose postvaccination. Noninferiority was met for all 4 QIV strains (table 2). Seroconversion rates (4-fold rise in preversus postvaccination HAI titer) were low but similar between groups (range, 21.3%-31.6%). A post hoc analysis showed similarpercentages of subjects achieving HAI titers ≥1:40 in groups 1 and 2, respectively, (90.6% and 89.3% for A/H1N1, 98.4% and 96.5% for A/H3N2, 49.2% and 46.5% for B/Brisbane, and 65.8% and 63.3% for B/Massachusetts). Responses for B strains were low in both groups. SAEs reported were consistent with conditions expected in this population; none were vaccine-related.
Conclusion.
Immune responses to PCV13 and QIV were non-inferior to PCV13 given alone, but associated with lower PCV13 responses that were significantly lower for 4 serotypes. Concomitant PCV13 and QIV administration yielded similar HAI responses compared to QIV alone, and was well tolerated. 
